| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IRAK1 |
| Uniprot No | P51617 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 194-712aa |
| 氨基酸序列 | RPFPFCWPLCEISRGTHNFSEELKIGEGGFGCVYRAVMRNTVYAVKRLKE NADLEWTAVKQSFLTEVEQLSRFRHPNIVDFAGYCAQNGFYCLVYGFLPN GSLEDRLHCQTQACPPLSWPQRLDILLGTARAIQFLHQDSPSLIHGDIKS SNVLLDERLTPKLGDFGLARFSRFAGSSPSQSSMVARTQTVRGTLAYLPE EYIKTGRLAVDTDTFSFGVVVLETLAGQRAVKTHGARTKYLKDLVEEEAE EAGVALRSTQSTLQAGLAADAWAAPIAMQIYKKHLDPRPGPCPPELGLGL GQLACCCLHRRAKRRPPMTQVYERLEKLQAVVAGVPGHSEAASCIPPSPQ ENSYVSSTGRAHSGAAPWQPLAAPSGASAQAAEQLQRGPNQPVESDESLG GLSAALRSWHLTPSCPLDPAPLREAGCPQGDTAGESSWGSGPGSRPTAVE GLALGSSASSSSEPPQIIINPARQKMVQKLALYEDGALDSLQLLSSSSLP GLGLEQDRQGPEESDEFQS |
| 预测分子量 | 76 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IRAK1重组蛋白的3篇参考文献及其摘要概述：
1. **文献名称**：*"Crystal structure of human IRAK1 kinase domain in complex with a potent inhibitor"*
**作者**：Wang et al.
**摘要**：该研究解析了IRAK1激酶结构域的晶体结构，并揭示了小分子抑制剂与其结合的模式，为靶向IRAK1的药物设计提供了结构基础。
2. **文献名称**：*"Recombinant IRAK1 production and its role in TLR/IL-1R signaling"*
**作者**：Kawai & Akira
**摘要**：通过重组表达IRAK1蛋白，验证其在TLR/IL-1R信号通路中的激酶活性及与MyD88的相互作用，阐明其在先天免疫中的调控机制。
3. **文献名称**：*"Functional characterization of IRAK1 splice variants using recombinant protein expression"*
**作者**：Huang et al.
**摘要**：研究利用重组IRAK1剪接变体蛋白，发现不同变体在NF-κB激活中的功能差异，揭示了剪接调控对炎症反应的潜在影响。
如需进一步扩展，可补充IRAK1重组蛋白在疾病模型中的应用研究文献。
**Background of IRAK1 Recombinant Protein**
Interleukin-1 receptor-associated kinase 1 (IRAK1) is a serine/threonine protein kinase critical in innate immune signaling, particularly within Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) pathways. It mediates downstream inflammatory and immune responses by linking receptor activation to intracellular signaling cascades, such as NF-κB and MAPK pathways, which regulate cytokine production, cell survival, and immune cell differentiation. Dysregulation of IRAK1 is implicated in autoimmune diseases, chronic inflammation, and cancers, making it a therapeutic target.
Recombinant IRAK1 protein is engineered using heterologous expression systems (e.g., *E. coli*, insect, or mammalian cells*) to produce purified, functional kinase for *in vitro* studies. This allows researchers to investigate IRAK1’s enzymatic activity, structure-function relationships, and interactions with signaling partners like MyD88. TRAF6. or IRAK4. Its recombinant form is vital for screening inhibitors, studying post-translational modifications (e.g., phosphorylation, ubiquitination), and modeling pathogenic mutations linked to immune disorders.
Structurally, IRAK1 contains an N-terminal death domain (mediating protein interactions), a central undetermined domain, and a C-terminal kinase domain. Recombinant variants often include tags (e.g., GST, His) for purification and detection. Studies using these proteins have clarified IRAK1’s role in TLR/IL-1R signaling, its autoactivation mechanism, and its cross-talk with other pathways, such as the NLRP3 inflammasome.
Research applications span drug discovery (e.g., targeting IRAK1 in lupus or lymphoma) and mechanistic studies of diseases like sepsis or rheumatoid arthritis. Challenges include maintaining kinase activity *in vitro* and mimicking native regulatory processes (e.g., IRAK4-mediated phosphorylation). Despite this, recombinant IRAK1 remains a cornerstone for dissecting immune signaling and developing targeted therapies.
×
